Tenaya Therapeutics Announces Interim Data from MyPEAK(TM)-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Stock Information for Tenaya Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tenaya Therapeutics Inc.

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Tenaya Therapeutics to Announce New Interim Data from MyPEAK(TM)-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE(TM)-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE(TM)-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.